A urine catecholamines test measures epinephrine, norepinephrine, and dopamine released into urine, usually over 24 hours. It can help evaluate disorders that produce excess catecholamines, including pheochromocytoma and sympathetic paraganglioma, and catecholamine-related testing also plays an important role in childhood neuroblastoma. For suspected pheochromocytoma or paraganglioma in adults, however, modern guidelines generally prefer plasma free metanephrines or urinary fractionated metanephrines because those metabolites are produced more continuously and are more sensitive than catecholamines themselves.
High urine catecholamines are not specific for cancer. Physical stress, severe pain, acute illness, exercise, nicotine, caffeine, sleep loss, hypoglycemia, and many medications can raise catecholamine output. Collection errors can also distort a 24-hour result. The level should therefore be interpreted against the laboratory’s own reference range and in the context of symptoms, medications, age, kidney function, and the reason testing was ordered. Marked or reproducible elevations usually lead to confirmatory biochemical testing and, when appropriate, imaging.
- What it measures: urinary epinephrine, norepinephrine, and dopamine, sometimes with related metabolites.
- Main tumor use in adults: evaluation of catecholamine-producing pheochromocytoma or paraganglioma, although metanephrines are generally preferred for initial testing.
- High result: may reflect a tumor, but stress, illness, stimulants, medications, or collection problems are common alternatives.
- Neuroblastoma testing: children are often evaluated with urinary catecholamine metabolites such as HVA and VMA, frequently as part of a broader panel.
- Reference range: there is no single universal normal value; use the age- and method-specific range on the laboratory report.
Table of Contents
- What catecholamines are
- Why urine catecholamines are ordered
- 24-hour urine collection and preparation
- What high urine catecholamines mean
- Non-tumor causes of high results
- Urine catecholamines and neuroblastoma
- Catecholamines versus metanephrines
- What happens after an abnormal result
What catecholamines are
Catecholamines are signaling chemicals produced mainly by the adrenal medulla and sympathetic nervous system. The three commonly measured compounds are epinephrine, norepinephrine, and dopamine.
Epinephrine and norepinephrine help the body respond to stress by increasing heart rate, blood pressure, cardiac output, and blood flow to muscles. Dopamine has several roles in the nervous system and is also a biochemical precursor to norepinephrine and epinephrine. After release, catecholamines are rapidly metabolized into other compounds, including metanephrine, normetanephrine, 3-methoxytyramine, vanillylmandelic acid (VMA), and homovanillic acid (HVA).
A 24-hour urine test captures catecholamines excreted throughout the day. That can be helpful because secretion may vary from hour to hour. Even so, direct catecholamine measurements are less sensitive for pheochromocytoma and paraganglioma than urinary fractionated metanephrines, which reflect continuous metabolism inside chromaffin cells and tumors.
Pheochromocytoma is a neuroendocrine tumor of adrenal medullary chromaffin cells. A sympathetic paraganglioma arises from related cells outside the adrenal gland, often in the abdomen, pelvis, or chest. These tumors may release norepinephrine, epinephrine, dopamine, or combinations of these chemicals.
The urine catecholamine test does not tell where a tumor is located, whether a mass is malignant, or whether symptoms are definitely caused by a tumor. It provides biochemical evidence that must be combined with other testing.
Catecholamine excess can be episodic or continuous
One reason symptoms and laboratory results do not always line up is that catecholamine release can occur in bursts. A person may have dramatic spells separated by hours or days of feeling normal. Triggers can include exercise, anesthesia, surgery, certain medications, abdominal pressure, or no obvious event at all. Other tumors produce a steadier norepinephrine excess that causes sustained hypertension rather than discrete attacks.
A 24-hour collection averages these patterns across an entire day, but it can still miss a relatively quiet tumor. Measuring metabolites helps because metanephrines are generated continuously within chromaffin tumor cells even between secretion episodes. This biochemical difference—not simply convenience—is the main reason metanephrines replaced direct catecholamines as the preferred screening measurement for adult PPGL.
Symptoms also do not reliably predict the degree of laboratory elevation. Some patients with large biochemical abnormalities have few recognizable attacks, while others with intense palpitations or sweating have normal tumor-directed testing because their symptoms come from another cause. Laboratory interpretation should therefore start with validated reference limits and sampling quality rather than symptom severity alone.
Why urine catecholamines are ordered
A clinician may order urine catecholamines when there is concern about excess sympathetic hormone production. In adults, the most important tumor-related question is usually whether a pheochromocytoma or paraganglioma is secreting catecholamines.
Possible reasons for testing include:
- episodic or sustained severe hypertension;
- attacks of headache, sweating, tremor, pallor, or palpitations;
- an adrenal mass that might be a pheochromocytoma;
- a known or suspected hereditary PPGL syndrome;
- follow-up of a previously treated catecholamine-producing tumor;
- pediatric evaluation for neuroblastoma using catecholamines and their metabolites.
These symptoms are not specific. Panic attacks, hyperthyroidism, pain, stimulant use, sleep apnea, withdrawal syndromes, arrhythmias, and many ordinary illnesses can cause similar episodes. That is why the test is most useful when the clinical suspicion is focused rather than when used as a general screen for nonspecific symptoms.
In a patient with an adrenal mass, biochemical testing has a special safety role. A catecholamine-producing pheochromocytoma should be recognized before biopsy or surgery because tumor manipulation can trigger dangerous surges in blood pressure and heart rate.
If the goal is specifically to rule out or confirm PPGL, many clinicians now start with plasma free metanephrines or 24-hour urinary fractionated metanephrines rather than catecholamines alone. Direct catecholamines may still be included in a panel or used to characterize secretion patterns.
24-hour urine collection and preparation
For adults, urine catecholamines are commonly measured in a 24-hour collection. The exact container, preservative, storage temperature, and dietary instructions vary by laboratory, so the collection kit instructions take priority.
A typical 24-hour collection follows this sequence:
- On the first morning, empty the bladder into the toilet and record the time.
- Collect every urine void after that for the next 24 hours.
- At the same time the following morning, collect the final void and add it to the container.
- Keep the specimen stored as directed and return it promptly.
Missing a void can make the measured daily excretion falsely low. Collecting beyond the exact 24-hour period can make it appear high. If a significant sample is lost, the laboratory may advise restarting the collection.
Medications, foods, and activity
Catecholamine testing is sensitive to sympathetic stimulation. Tell the clinician about prescription medicines, over-the-counter decongestants, antidepressants, ADHD medications, levodopa, nicotine, caffeine, supplements, and recreational stimulants. Some drugs raise catecholamine release, while others can interfere with a particular analytical method.
Do not stop a prescribed medicine without medical advice. In many cases, the safest approach is to continue necessary treatment and interpret the result with the medication documented. If a borderline result is difficult to explain, the clinician can decide whether repeat testing under different conditions is appropriate.
Strenuous exercise, severe pain, acute illness, emotional stress, hypoglycemia, and inadequate sleep can increase catecholamine output. When possible, a planned outpatient collection during stable health is easier to interpret than a collection performed during an emergency or hospitalization.
Completeness of a timed collection is one of the first issues checked when a result is unexpected. Missing one void can underestimate total excretion, while collecting beyond the assigned period can increase it. The laboratory may measure urine creatinine or total volume as a rough check on collection plausibility, but those measures do not prove that every sample was captured. Patients should record the exact start and stop times and tell the laboratory if urine was missed rather than trying to compensate later.
What high urine catecholamines mean
A high result means one or more catecholamines were excreted above the laboratory’s reference interval. The magnitude and pattern matter more than the word “high” alone.
A mild elevation is commonly caused by non-tumor factors. A value only slightly over the upper limit may be difficult to interpret if the patient was acutely ill, exercised heavily, used nicotine, drank substantial caffeine, or was taking a medication that increases sympathetic activity.
A marked and reproducible elevation is more concerning, particularly when symptoms or imaging also suggest PPGL. There is no universal multiple of the upper limit that proves a catecholamine-producing tumor, but results several times above the reference limit deserve careful specialist assessment.
The pattern can give clues:
- predominant norepinephrine elevation is common in many sympathetic paragangliomas and some pheochromocytomas;
- epinephrine production is more typical of adrenal medullary tumors with the relevant biochemical machinery;
- substantial dopamine elevation can occur in selected paragangliomas and neuroblastic tumors, but also has non-tumor and medication-related causes.
A normal urine catecholamine result does not reliably exclude PPGL. Some tumors release catecholamines intermittently, and small or biochemically quiet tumors may not produce a dramatic direct catecholamine signal. Metanephrine testing is more sensitive for that reason.
Why there is no universal “normal range”
Laboratories use different units, analytical platforms, reference populations, and age adjustments. A report may express results in micrograms per 24 hours, nanomoles per day, or other units. Dopamine reference intervals also differ substantially by age, especially in children.
The correct comparison is therefore the value against the upper reference limit on the same report. Online ranges from another laboratory should not be used to reinterpret a result. If testing is repeated for follow-up, using the same laboratory and method can make trends easier to assess.
Non-tumor causes of high results
High urine catecholamines often have causes other than a neuroendocrine tumor. The sympathetic nervous system reacts to many forms of physical and psychological stress.
Common contributors include:
- acute pain or severe illness;
- fever, hypoglycemia, or dehydration;
- vigorous exercise;
- anxiety or marked emotional stress;
- obstructive sleep apnea;
- nicotine or stimulant exposure;
- caffeine, depending on intake and laboratory instructions;
- decongestants containing sympathomimetic drugs;
- amphetamines and some ADHD medications;
- certain antidepressants and monoamine oxidase inhibitors;
- levodopa and other drugs affecting dopamine metabolism;
- withdrawal from alcohol, clonidine, benzodiazepines, or other sedating agents.
Collection error is another major source of misleading results. A large urine volume does not automatically mean the collection was complete, and a small volume does not automatically mean it was incomplete. Laboratories may use urinary creatinine as a rough check, but age, sex, body size, and muscle mass affect creatinine excretion.
Kidney function also influences urinary handling. In advanced renal impairment, a clinician may favor plasma-based testing or consult the laboratory about interpretation.
A false-positive result is more likely when the elevation is modest and there is a clear competing explanation. It is less reassuring to dismiss a high result when the person also has an adrenal mass, classic spells, a pathogenic PPGL-related gene variant, or a previous catecholamine-producing tumor.
Timing matters during follow-up as well. If the purpose is surveillance after treatment, comparing the new result with the patient’s own pretreatment biochemical pattern can be more useful than comparing every analyte equally. A tumor that originally produced mainly norepinephrine may be monitored differently from one that was dopamine-predominant. Specialists often use the same laboratory method when possible so analytical changes do not masquerade as biological recurrence. When a previous tumor was biochemically silent, however, normal catecholamines during follow-up cannot provide the same reassurance, and imaging or other surveillance tools may carry more weight. This is another reason the original tumor’s biochemical phenotype should remain part of the long-term record.
Urine catecholamines and neuroblastoma
Neuroblastoma is a pediatric cancer arising from developing sympathetic nervous system tissue, most often in the adrenal gland or paraspinal sympathetic chain. Unlike adult PPGL testing, neuroblastoma evaluation has traditionally relied heavily on urinary catecholamine metabolites, especially HVA and VMA.
These metabolites are elevated in many children with neuroblastoma, but not in every case. Modern pediatric research shows that broader panels including dopamine, norepinephrine, normetanephrine, metanephrine, and 3-methoxytyramine can improve diagnostic sensitivity compared with HVA and VMA alone.
A 2023 multicenter study involving 400 children with neuroblastoma found that an eight-metabolite urinary panel had better diagnostic accuracy than the traditional HVA/VMA combination. It also reported similar diagnostic sensitivity for spot urine and 24-hour urine measurements when results were handled appropriately, leading the study group to recommend spot urine as standard practice for neuroblastoma catecholamine metabolite diagnostics.
This pediatric use should not be confused with an adult 24-hour catecholamine test for pheochromocytoma. Children have strongly age-dependent reference ranges, and results are often normalized to urine creatinine. A pediatric oncology or metabolic laboratory should interpret them.
Other neuroendocrine tumors use different biomarkers. For example, serotonin-producing neuroendocrine tumors are more directly evaluated with urine 5-HIAA, not catecholamines.
Catecholamines versus metanephrines
The central practical point is that metanephrines are generally preferred for initial PPGL testing. Tumor cells continuously convert catecholamines into metanephrines, so metanephrine levels can remain elevated even when the tumor is not actively releasing a catecholamine burst during the collection period.
| Test | What it measures | Best-established role |
|---|---|---|
| Urine catecholamines | Epinephrine, norepinephrine, dopamine | Characterizing catecholamine secretion; adjunctive tumor evaluation |
| Urine fractionated metanephrines | Metanephrine and normetanephrine | First-line biochemical testing for PPGL |
| Plasma free metanephrines | Free metanephrine and normetanephrine | Highly sensitive first-line PPGL testing with controlled sampling |
| Urine HVA/VMA and broader metabolite panels | Dopamine and catecholamine metabolites | Adjunctive diagnosis and monitoring of neuroblastoma |
A broad marker such as chromogranin A is not a substitute for catecholamine or metanephrine testing when a catecholamine-producing tumor is suspected because many non-tumor conditions can change chromogranin A.
What happens after an abnormal result
A mildly abnormal urine catecholamine test usually triggers verification, not an immediate tumor diagnosis. The clinician reviews symptoms, medications, stimulants, collection quality, acute illness, and kidney function. In adults with suspected PPGL, the next biochemical step is often plasma free or urinary fractionated metanephrines under controlled conditions.
If biochemical evidence is strongly positive, CT or MRI is used to locate an adrenal or extra-adrenal mass. Functional imaging can be added when there is concern for hereditary, multifocal, recurrent, or metastatic disease. Confirmed PPGL also usually prompts discussion of genetic testing because inherited susceptibility is common enough to affect management and family screening.
If the test was ordered for a child with possible neuroblastoma, follow-up is different and may include imaging, a broader urinary metabolite panel, tumor-specific nuclear imaging, and pediatric oncology evaluation.
Urgent assessment is warranted for severe symptomatic hypertension, chest pain, fainting, stroke-like symptoms, severe shortness of breath, or a sudden intense headache with very high blood pressure. These can represent a catecholamine crisis or another cardiovascular emergency and should not wait for outpatient laboratory follow-up.
The most useful way to read a catecholamine report is to ask three questions: Which analyte is elevated? How far above the laboratory limit is it? Were the collection and clinical conditions good enough to trust the result? Those answers usually determine whether repeat testing or imaging is the next rational step.
Collection completeness matters especially when a 24-hour result is only mildly abnormal. Missing one or more voids can underestimate excretion, while collecting beyond the instructed interval can inflate it. Laboratories may use total urine volume, collection duration, and sometimes urine creatinine as clues to whether the specimen is plausible. If the collection was clearly incomplete, repeating it correctly is often more informative than interpreting the original number too precisely.
References
- Catecholamines and Metanephrines: Quantification in the Diagnosis of Pheochromocytoma and Paraganglioma, Considerations and Critical Issues 2026 (Review)
- Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician 2023 (Review)
- Biochemical Assessment of Pheochromocytoma and Paraganglioma. 2023 (Review)
- Update on the diagnosis of the pheochromocytoma. 2025 (Review)
- Optimising urinary catecholamine metabolite diagnostics for neuroblastoma 2023
- Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinations 2024
Disclaimer
This article is for general education and does not replace individualized medical care. Urine catecholamine reference ranges, medication effects, and collection requirements differ by laboratory and age. Do not stop prescription medicines before testing unless a qualified clinician specifically advises you to do so.
